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Multiple	 sclerosis	 is	 an	 inflammatory	 neurological	 disease	 of	 young	 adults	 that	 leads	 to	
numerous	therapeutic	problems	and	to	severe	disability.	Glatiramer	acetate	(GA)	is	a	disease-
modifying	drug	used	frequently	for	long-term	treatment	of	the	disease.	We	investigated	the	
impact	of	GA	 treatment	on	 the	parameters	of	 reversal-pattern	visual	 evoked	potentials	 and	
event-related	 P300	 wave	 (reflecting	 visual	 acuity	 and	 cognitive	 dysfunction).	 Relapsing-
remitting	multiple	sclerosis	patients	either	subjected	to	one-year-long	continuous	treatment	
with	GA	or	without	any	disease-modifying	therapy	and	also	healthy	controls	were	involved	
in	the	study.	The	above-mentioned	parameters	were	analyzed	at	two	time	points,	at	the	first	
recording	and	after	one	year.	It	was	found	that	GA	did	not	exert	a	significant	influence	on	the	
phenomena	studied	at	least	during	the	one-year	follow-up.	This	finding	is	in	contrast	to	most	
of	the	clinical	observations.
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INTRODUCTION
Multiple	sclerosis	(MS)	is	one	of	the	most	debilitating	
inflammatory	 neurological	 diseases	 of	 young	 adults.	
Patients	 gradually	 lose	 their	 ability	 to	 deal	 with	
common	daily	activities;	as	an	end-point,	they	become	
totally	dependent	and,	sadly,	a	burden	to	society.	From	
this	viewpoint,	an	early	proper	diagnosis	of	the	disease	
is	 mandatory	 in	 order	 to	 delay,	 as	 long	 as	 possible,	
major	disability.	A	valuable	tool	in	fulfilling	this	task	
is	 testing	 evoked	 potentials	 (EPs).	 Introduced	 into	
practice	in	the	1950s,	some	of	these	neurophysiological	
methods	constitute	a	useful	diagnostic	and	prognostic	
tool.
One	 can	 define	EPs	 as	EEG-derived	 responses	 of	
the	CNS	to	external	stimuli.	Stimuli	are	differentiated,	
according	 to	 the	 involved	 sensory	 system,	 visual,	
auditory,	 or	 somatosensory.	 The	 EPs	 recorded	 over	
different	body	 regions	are	classified	as	near-field	or	
far-field	 potentials,	 according	 to	 the	 distance	 of	 the	
neural	 generator	 from	 the	 recording	 place.	Another	
classification	 involves	 as	 a	 criterion	 the	 cognitive	
participation	 of	 the	 subject;	 if	 present,	 we	 refer	 to	
it	 as	 event-related	 potentials	 (ERPs),	 if	 not,	 then	 as	
stimulus-related	 evoked	 potentials	 (EPs).	 We	 have	
used	both	categories,	visual	EPs	(VEPs),	as	stimulus-
related,	and	the	P300	wave	as	an	ERP.	
Through	demyelination,	MS	affects	the	conductivity	
in	 the	CNS,	 this	being	mirrored	by	 the	EP	 latencies.	
When	nerve	fibers	are	affected,	amplitude	changes	can	
also	be	 assumed.	The	disease	 starts	 quite	 frequently	
under	the	form	of	a	clinically	isolated	syndrome,	with	
visual	 symptoms	 in	most	cases.	For	 this	 reason,	VEP	
recording	 might	 be	 helpful,	 revealing	 pathological	
findings	even	under	circumstances	when	the	sensitivity	
of	 imaging	 techniques	 is	not	 enough.	As	 the	disease	
progresses	 and	 the	 extent	 of	 tissue	 loss	 becomes	
important,	a	variable	degree	of	cognitive	dysfunction	
might	 install.	A	feasible	approach	 to	characterize	 the	
effect	 is	 theoretically	 the	 P300	 wave,	 an	 objective	
measure	for	certain	cognitive	processes.
Visual	 EPs	 are	 the	 most	 commonly	 used	 evoked	
brain	 responses	among	 the	diagnostic	procedures	 for	
MS.	When	 retrobulbar	optical	 neuropathy	 is	 present	
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(as	 the	 basis	 of	 a	 clinically	 isolated	 syndrome	 or	 a	
relapse),	VEPs	are	impaired.	These	changes	are	either	
prolongation	 of	 the	 latency	 (a	 part	 of	 the	 revised	
McDonald	criteria	 [1]),	or	decrease	 in	 the	amplitude	
[2],	or	even	changes	in	the	component	morphology	[3].
A	 key	 issue	 when	 assessing	 the	 efficacy	 of	 a	
disease-modifying	drug	 is	 to	 find	objective	measures	
of	 the	 corresponding	 pharmacological 	 effect .	
Recording	of	VEPs	were	proposed	for	this.	According	
to	a	study	using	 interferon	beta-1a	for	MS	treatment,	
there	 was	 no	 impact	 observed	 on	 these	 potentials	
[4],	 while	 other	 researchers	 reported	 significant	
changes	 [5].	 Natalizumab	 showed	 an	 even	 better	
profile	observed	after	one	year	of	treatment,	 this	was	
ameliorating	 the	 electrophysiological	 parameters	 of	
VEPs,	 somatosensory	EPs,	and	motor	EPs	 [6].	For	a	
drug	used	 in	 the	 treatment	of	MS,	such	as	glatiramer	
acetate	(GA),	the	available	data	are	poor	and	indirect	
[7],	and	this	explains	the	need	to	evaluate	GA’s	impact	
on	VEPs.		
Event-related	 potentials,	 similarly	 to	 other	 EPs,	
are	 conditioned	 for	 normality	 by	 the	 integrity	 of	
conduction	 in	 the	CNS;	 the	state	of	 the	white	matter	
is	 crucially	 important.	 Even	 the	 smallest	 degree	 of	
demyelination	 can	 influence	 the	 conductance	 in	 the	
CNS,	causing,	at	least	theoretically,	different	degrees	
of	 cognitive	 dysfunction.	 According	 to	 the	 initial	
viewpoint,	 the	 cognitive	 EPs	 allow	 us	 to	 identify	
even	 the	 slightest	 changes	before	 relevant	 results	of	
standard	neuropsychological	tests	[8].	
The	 P300	 (P3)	 is	 a	 positive	 EEG-derived	 (also	
by	 the	 averaging	 technique)	 deflection	 observed	
approximately	 300	 msec	 after	 triggering;	 it	 can	 be	
elicited	by	 either	visual,	 auditory,	or	 somatosensory	
stimuli.	It	includes	two	main	components,	P3a	and	P3b,	
which	are	not	always	identifiable	separately.	These	are	
waves	corresponding	to	the	main	supposed	generators,	
the	dopaminergic	 frontal	and	noradrenergic	 temporal	
ones	[9].	The	investigated	parameters	of	P300	usually	
are	 the	 latencies;	 the	amplitudes	are	characterized	by	
high	inter-	and	intrapersonal	variability.	
Latency	changes	of	P300	in	MS	were	reported	in	the	
literature	 (prolongation	when	compared	with	normal	
[10,	 11]),	 and	 the	 test	was	 even	 used	 for	 evaluation	
of	 evolution	 of	 the	 disease	 and	 response	 to	 therapy	
[12,	13].	The	wave	was	even	investigated	as	a	tool	to	
predict	treatment	responses	to	a	symptomatic	approach	
with	modafinil	 and	 found	 to	 show	 such	 a	 role	 [14].	
The	P300	 test	was	proposed	 recently	as	an	objective	
method	 for	 evaluation	of	 cognitive	dysfunction	 also	
for	pediatric	patients	[15].	
As	was	mentioned	above,	we	have	only	indirect	data	
with	 respect	 to	ERPs	 in	 the	 case	 of	GA	 [14].	There	
is	only	one	prospective	study	stating	a	positive	effect	
of	 a	 one-year-long	 interferon	 beta-1b	 treatment	 on	
the	P300	parameters	in	MS	patients	[16].	Considering	
these,	 we	 have	 tried	 to	 evaluate	 the	 effects	 of	 GA	
treatment	on	VEPs	and	cognitive	ERPs	(P300).
METHODS
Our	 study	 was	 performed	 on	 relapsing-remitting	
multiple	 sclerosis	 (RRMS)	 patients	 admitted	 to	 the	
Neurology	 Clinic	 of	 the	 Cluj	 County	 Emergency	
Hospital	(Romania).	
The	 impact	of	GA	 treatment	on	 the	parameters	of	
two	EEG	phenomena,	 the	 reversal-pattern	VEPs	and	
event-related	 P300	 wave	 (reflecting	 visual	 acuity	
and	cognitive	dysfunction),	was	 investigated	 in	 three	
groups	of	participants.	Group	1	(hereafter,	GA-treated,	
n	=	21)	 consisted	of	patients	with	RRMS	diagnosis.	
TABLE 1. Examined Groups 1-3 Consisted of Relapsing-Remitting Multiple Sclerosis (RRMS) Patients and Healthy Individuals 
(Control)
Т а б л и ц я 1. Досліджені групи 1-3, сформовані з пацієнтів, які страждали від розсіяного склерозу, та здорових суб’єктів 
(контроль) 
Indices
Groups
1	(glatiramer	acetate-treated	
RRMS	patients,
n	=	21)
2	(untreated	RRMS	patients,	 
n	=	14) 3	(control,	n	=	12)
Age,	years 36.67	±	2.15 37.36	±	2.05 35.83	±	2.82
Men	 6	(28.6%) 4	(28.6%) 4	(33.33%)
Women	 15	(71.4%) 10	(71.4%) 8	(66.7%)
EDSS 2.59	±	0.18 2.50	±	0.27
Footnote.	Means	±	s.d. are	shown.
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The	 above-mentioned	 parameters	 were	 analyzed	
at	 inclusion	 (when	 the	 first	 recording	 took	 place)	
and	 after	 one	year	 of	 continuous	 treatment	with	GA	 
(20	mg	per	day,	subcutaneous	daily	injections);	 these	
time	 points	 of	 the	 analysis	 are	 designated	 below	 as	
time	points	I	and	II,	respectively.	Group	2	(hereafter,	
untreated,	 n	 =	 14)	 also	 included	 RRMS	 patients	
examined	 at	 inclusion	 in	 the	 study	 (time	 point	 I	
of	 examination)	 and	 after	 one	 year	 but	without	 any	
disease-modifying	 treatment	 (time	point	 II).	Group	3	
(control,	n	=	12)	was composed	of	healthy	individuals	
(with	 only	 one	 evaluation	 of	 the	 investigated	
parameters).	
Patients	with	mental	retardation,	diabetes mellitus,	
dyselectrolytemias,	and	psychiatric	comorbidities	were	
not	included	in	the	tested	groups,	and	the	presence	of	
any	sight	or	hearing	disturbance	was	also	an	exclusion	
criterion.
Age	was	comparable	 in	 the	groups;	 as	 for	 the	 sex	
of	 the	participants,	 the	distribution	was	 identical	 for	
both	 RRMS	 groups	 (GA-treated	 and	 untreated)	 and	
somewhat	 different	 for	 the	 controls.	 Another	 key	
parameter	for	two	former	groups	was	the	EDSS	score	
at	inclusion,	which	showed	no	statistical	differences	at	
the	beginning	of	the	study	(Table	1).
After	 groups	 had	 been	 formed,	 evaluation	 started	
using	 reversal-pattern	 VEP	 and	 auditory-induced	
P300	 recordings.	 A	 Medtronic	 Keypoint	 4	 device	
(Medtronic-Dantec,	 Denmark)	 was	 used	 to	 trigger	
and	 record	VEPs,	with	 12×16	 sized	 checkers,	 using	
a	resolution	of	30	msec,	20	mV	per	division,	low-pass	
filter	 at	1	Hz,	high-pass	 filter	 at	0.2	kHz,	maximum	
tolerated	impedance	of	recording	electrodes	5	kW,	and	
stimulation	frequency	1	sec–1.	An	active	electrode	was	
placed	 in	Oz,	a	 reference	 in	Fz,	and	a	grounding	one	
in	Cz,	 according	 to	 the	10-20	 system.	Each	eye	was	
stimulated	 twice,	with	an	average	of	50	stimuli.	The	
latency	 and	 amplitude	 of	 the	N75,	 P100,	 and	N135	
components	 were	 measured;	 waveforms	 were	 also	
compared.
The	 same	 device	 was	 also	 used	 to	 record	 the	
P300	wave.	Acoustic	 stimuli	were	presented	 through	
earphones	according	to	the	oddball	paradigm,	using	a	
resolution	of	100	msec,	50	mV	per	division,	low-pass	
frequency	at	0.2	Hz,	high-pass	at	0.1	kHz,	maximum	
tolerated	 impedance	of	 the	electrodes	1	kW,	variable	
stimulation	 frequency	 between	 0.3	 and	 1	 sec–1,	
percentage	of	the	odd	stimuli	15%,	frequency	of	these	
stimuli	2,000	Hz,	and	that	of	frequent	ones	1,000	Hz.	
Recordings	were	made	with	electrodes	placed	 in	Fz,	
Cz,	and	Pz	of	 the	10-20	system;	 reference	electrodes	
were	positioned	 in	A1	and	A2,	 and	 a	grounding	one	
in	 Fpz.	 The	 percentage	 of	 hits	 and	 number	 of	 false	
hits	 were	 recorded	 using	 a	 neurofeedback	 setting;	
the	reaction	 time	was	also	recorded.	Two	evaluations	
were	 performed	 for	 each	 subject,	 with	 a	 total	 of	
150	 averages	 and	22-23	 odd	 sounds/evaluation.	The	
recorded	parameters	were	 the	 latency	and	amplitude	
of	P300,	 the	percentage	of	hits,	number	of	 false	hits,	
and	reaction	time.	
Statistical	analysis	was	performed	using	Microsoft	
Excel,	 SPSS	 17,	 and	 Statistica	 4.5	 software.	After	
calculation	 of	 means	 and	 s.e.,	 the	 paired	 t-test	 and	
variance	 analysis	 (ANOVA)	were	 used,	 followed	by	
post-hoc	 analysis,	 with	 the	 Scheffé	 or	 Dunnett	 T3	
test,	 depending	 on	 the	 variance	 equality.	 For	 other	
circumstances,	 when	 parametric	 testing	 was	 not	
allowed,	 nonparametric	 tests	 were	 chosen	 (such	 as	
Wilcoxon,	 Mann–Whitney	 U,	 and	 Kruskal–Wallis).	
For	 multiple	 comparisons,	 log-linear	 analysis	 was	
used.	The	threshold	P	value	for	significance	for	each	
test	was	P	<	0.05.
RESULTS
VEP Testing.	 First,	 it	 should	 be	 mentioned	 that	
normal	and	W-shaped	VEP	waveforms	were	observed	
in	groups	1	and	2	of	RRMS	patients	(Fig.	1).
Raw	data	were	 tested	 first	using	 the	Kolmogorov–
Smirnov	 test	 (all	 groups	 demonstrated	 normal	
distributions;	 not	 shown).	 Still,	 considering	 the	
small	 number	 of	 participants,	 both	 parametric	 and	
nonparametric	tests	were	performed.
Statistical	analysis	began	with	the	evaluation	of	the	
obtained	 latencies.	We	measured	differences	between	
the	left	and	right	latencies	of	the	VEP	components	for	
RRMS	patients	and	found	that	some	asymmetry	might	
be	present,	but	its	degree	was	quite	comparable	in	all	
three	groups	 (GA-treated,	untreated,	and	control;	not	
shown).	There	were	no	significant	differences	after	the	
one-year	follow-up	in	the	individual	groups.	
The	next	aspect	was	to	check	if	significant	changes	
appeared	 between	 the	 groups	 compared	 with	 the	
parameters	 of	 the	 control	 group.	 Variance	 analysis	
and	the	Levene	test	for	the	homogeneity	of	variances	
were	used,	and	it	was	found	that	equal	variances	could	
not	 be	 assumed.	Therefore,	we	 applied	ANOVA	and	
post-hoc	 analysis	 with	 the	Dunnett	 T3	 test	 doubled	
by	 their	 nonparametric	 equivalences,	 the	 Kruskal–
Wallis	and	Mann–Whitney	U	tests	(taking	into	account	
the	 small	 number	 of	 patients/controls;	 Fig.	 2).	 As	
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this	 diagram	 demonstrates,	 the	 latencies	 of	 all	VEP	
components	 in	both	RRMS	groups	were	significantly	
longer,	 as	 compared	with	 those	 in	 healthy	 controls,	
independently	 of	 the	 time	 points	 of	 the	 analysis.	At	
the	 same	 time,	 there	were	no	 significant	differences	
between	the	GA-treated	(after	one-year-long	treatment	
with	GA)	and	untreated	groups.
The	 next	 step	 was	 to	 check	 the	 variation	 in	 the	
amplitudes	 of	 VEP	 components	 using	 the	 same	
paradigm.	 The	 Kolmogorov–Smirnov	 test	 proved	
the	 normality	 of	 the	 groups	 for	 this	 parameter	 also.	
Then,	 descriptive	 statistics	 and	 asymmetry	 testing	
were	 performed;	 changes	 in	 the	 treated	 group	 and	
differences	 after	 one	 year	 of	 therapy	were	 detected	
for	 components	 P100	 and	N135.	 Similar	 significant	
changes	 were	 found	 also	 for	 N75	 after	 one	 year	 in	
the	 untreated	 group.	Another	 noticeable	 difference	
was	the	amplitude	reduction	on	both	sides	in	the	N75	
n=108
Left Oz­Fz
Left Oz­Fz
Right Oz­Fz
Right Oz­Fz
A B
n=100
n=106
n=104
2 μV 2 μV
30 msec 30 msec
F i g. 1.	Examples	of	visual	evoked	potentials	observed	in	patients	of	groups	1	and	2;	normal	(A)	and	W-shaped	(B)	P100	waveforms	are	
shown.	
Р и с. 1. Приклади	зорових	викликаних	потенціалів,	спостережуваних	у	пацієнтів	груп	1	та	2;	показано	нормальні	та	W-подібні	
форми	хвилі	потенціалу	P100	(А та	B	відповідно).
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F i g. 2.	Mean	latencies	of	the	components	of	the	visual	EP	in	relapsing-remitting	multiple	sclerosis	(RRMS)	patients	treated	with	glatiramer	
acetate,	GA,	in	time	points	I	and	II	of	the	analysis,	i.e.,	at	the	first	recording	and	after	one	year	of	continuous	treatment	with	GA	(1),	in	
untreated	RRMS	patients	in	time	points	I	and	II,	i.e.,	at	the	first	recording	and	after	one	year	(2),	and	in	healthy	individuals	(control,	3).	 
*	Significant	difference	from	the	control.
Р и с. 2.	Середні	величини	латентних	періодів	компонентів	зорових	ВП	у	пацієнтів	із	розсіяним	склерозом	(РС),	котрі	проходили	
лікувальний	 курс	 із	 застосуванням	 глатирамеру	 ацетату	 (ГА),	 у	 моменти	 часу	 I	 і	 II,	 тобто	 під	 час	 першої	 реєстрації	 та	 за	 рік	
безперервного	лікування	(1),	у	пацієнтів	із	РС,	котрі	не	отримували	лікування,	у	моменти	часу	I	і	II,	тобто	під	час	першої	реєстрації	
та	за	рік	(2)	та	у	здорових	людей	(контроль,	3).
I II
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component	after	one	year	of	treatment.	
The	 intragroup	 analysis	 was	 followed	 by	 the	
intergroup	comparison,	using	the	same	tests	as	for	the	
latencies	(Fig.	3).
The	morphology	of	the	VEPs	was	tested	using	log-
linear	analysis.	The	crosstab	used	and	 the	 results	are	
shown	in	Table	2.
Observing	 the	 frequencies,	 one	 can	 notice	 the	
differences	 at	 inclusion	 in	 the	 study	 between	 the	
GA-treated	 and	 untreated	 groups.	 Because	 VEP	
morphology	 was	 not	 a	 selection	 criterion,	 different	
frequencies	 were	 found	 at	 the	 start	 of	 the	 study.	
Evaluation	continued	for	one	year;	so,	the	initial	data	
had	 no	 impact	 on	 the	 treatment-induced	 variability.	
For	each	principal	effect	 (treatment,	 time	point,	 and	
morphology),	 the	observed	 frequencies	differed	 from	
the	expected	values.	As	a	result,	the	three-dimensional	
frequency	 analysis	 revealed	 a	 model	 with	 high	
adequation	of	the	observed	and	anticipated	frequencies	
in	 the	 case	 of	 association	 of	 the	 principal	 effect	 of	
time	point	 (at	 inclusion	vs	 one-year	 follow-up),	 and	
the	 interaction	 between	 treatment	 and	 morphology.	
The	latter	 interaction	fits	 the	model	with	even	higher	
adequation,	but	it	is	bi-dimensional.	
The	most	constant	effect	was	given	by	the	moment	
of	examination;	 the	 impact	of	GA	treatment	over	 the	
frequency	of	the	W-like	morphology	is	significant,	the	
latter	index	being	increased.
P300 Testing. After	 raw	 data	 related	 to	 the	 P300	
were	 recorded,	 we	 proceeded	 as	 with	 the	 VEP	
parameters:	 every	 group	 was	 tested	 for	 normality	
with	 the	 help	 of	 the	Kolmogorov–Smirnov	 test,	 and	
the	 distributions	 were	 found	 to	 be	 normal.	 Then,	
descriptive	statistics	were	performed,	and	the	latency	
values	in	the	two	time	points	were	tested	within	groups	
(not	 shown).	There	was	a	 significant	 increase	 in	 the	
latency	 values	 in	 the	 case	 of	 the	 GA-treated	 group	
during	 the	 investigated	 period.	 For	 the	 intergroup	
comparison,	there	was	only	one	significant	difference;	
when	the	starting	values	in	the	GA-treated	group	were	
compared	 with	 the	 control,	 slightly	 smaller	 values	
were	observed,	but	 the	difference	disappeared	during	
the	one-year-long	treatment.	In	this	case,	we	used	the	
Scheffé	 test	 for	post-hoc	 analysis,	 since	 the	Levene	
TABLE 2. Crosstab of the Frequencies of Relapsing-Remitting Multiple Sclerosis Patients Treated with Glatiramer Acetate (GA) 
and Untreated Patients (UT) According to the Treatment Status, Time Points I and II of Examination, and Morphology of the Visual 
Evoked Potentials, and also the Analysis of the Models Containing Principal Effects and Interactions
Т а б л и ц я 2. Перехресна таблиця частотності пацієнтів, котрі страждали від розсіяного склерозу (РС), після лікування із 
застосуванням глатирамеру ацетату (ГА) та пацієнтів з РС, які не приймали ГА згідно зі статусом лікування, моментів часу  
I і II у перебігу обстеження та морфології зорових викликаних потенціалів, а також аналіз моделей, що містять у собі основні 
ефекти та взаємодії
Models
Treatment Time	point Morphology    
1 2 3    
 χ2 df P χ2 df P χ2 df P    
Max	likelihood	χ2 61.25 6 0.000 67.61 6 0.000 14.55 6 0.024
Pearson	χ2	 55.03 6 0.000 69.84 6 0.000 14.24 6 0.027
 1	2	3 1	2 1	3	 2	3 Treat Time Morph Freq %
 χ2 df P χ2 df P χ2 df P χ2 df P
GA
I
W 4 9.52%
Max	likelihood	χ2 8.13 4 0.087 61.23 5 0.000 8.16 5 0.148 14.52 5 0.013 N 38 90.48%
Pearson	χ2	 8.15 4 0.086 54.93 5 0.000 8.21 5 0.145 14.18 5 0.015
II
W 6 14.29%
 321 21 31 32 N 36 85.71%
 χ2 df P χ2 df P χ2 df P χ2 df P
UT
I
W 9 32.14%
Max	likelihood	χ2	 0.00 0 1 61.18 4 0.000 0.50 4 0.973 14.43 4 0.006 N 19 67.86%
Pearson	χ2	 0.00 0 1 54.97 4 0.000 0.50 4 0.974 14.17 4 0.007
II
W 8 30.77%
 1	32 21	3 2	31    N 18 69.23%
 χ2 df P χ2 df P χ2 df P    
Max	likelihood	χ2	 8.05 3 0.045 8.09 3 0.044 0.47 3 0.925
Pearson	χ2 8.20 3 0.042 8.12 3 0.044 0.47 3 0.925
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test	proved	that	variances	were	comparable	(the	Sheffé	
test	being	more	robust	than	the	Dunnett	test)	(Fig.	4).
In	the	GA-treated	group,	the	P300	amplitude	showed	
a	significant	increase	for	the	Cz	and	Pz	recordings	and	
a	marginally	significant	shift	for	Fz	after	one-year-long	
therapy.	 In	 the	untreated	group,	no	such	change	was	
detectable,	 although	 a	 trend	 toward	 an	 increase	was	
noticeable.	Since	normal	distribution	was	the	case	for	
the	amplitudes	too	and	the	variances	were	comparable,	
an	ANOVA-Scheffé	 combination	was	 used,	 doubled	
with	 the	 nonparametric	 analogs.	 Slight	 differences	
were	detected	for	the	Pz	recording	in	the	case	of	GA-
treated	group	vs	controls.	More	interestingly,	after	the	
one-year	follow-up,	both	RRMS	groups	demonstrated	
significantly	 higher	 amplitudes	 for	 Fz	 recordings	
than	 the	control,	 still	without	 significant	differences	
between	them	(Fig.	5).	
In	the	case	of	neurofeedback	parameters	(hits,	false	
hits,	 and	 reaction	 time),	 the	 Kolmogorov–Smirnov	
test	 proved	 that	 the	 distribution	was	 not	 normal	 for	
some	of	the	measures.	As	a	consequence,	we	decided	
to	use	nonparametric	tests	(Kruskal–Wallis	and	Mann–
Whitney	U),	since	the	Wilcoxon	test	criteria	were	also	
not	satisfactory	due	to	the	lack	of	correspondence.	No	
significant	changes	were	detected	for	the	investigated	
measures,	although	 it	was	noticeable	 that,	after	one-
year-long	GA	 treatment,	 both	 the	 percentage	 of	 hits	
and	 the	 reaction	 time	 became	 better,	 but	 only	 with	
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F i g. 3. Mean	amplitudes	of	the	components	of	visual	evoked	potentials	in	the	three	examined	groups.	Designations	are	the	same	as	in	Fig.	2.	
Р и с. 3.	Середні	величини	амплітуд	компонентів	зорового	ВП	у	трьох	обстежених	групах.
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F i g. 4.	P300	latencies	in	relapsing-remitting	multiple	sclerosis	(RRMS)	patients	treated	with	glatiramer	acetate	(GA)	in	time	points	I	and	
II	of	examination,	i.e.,	at	the	first	recording	and	after	one	year	of	continuous	treatment	with	GA,	GAI	and	GAII,	respectively),	in	untreated	
RRMS	patients	in	time	points	I	and	II,	i.e.,	at	the	first	recording	and	after	one	year,	UTI	and	UTII),	and	in	control	healthy	individuals	(Ctrl.);	
1-3	correspond	to	Fz,	Cz,	and	Pz	recordings,	respectively.
Р и с. 4.	 Латентні	 періоди	 потенціалу	 P300	 у	 пацієнтів	 із	 розсіяним	 склерозом	 (РС),	 котрі	 проходили	 лікувальний	 курс	 із	
застосуванням	глатирамеру	ацетату	(ГА)	у	моменти	часу	I	і	II,	тобто	під	час	першої	реєстрації	та	за	рік	безперервного	лікування,	
GAI	та	GAII	відповідно,	у	пацієнтів	із	РС,	котрі	не	отримували	лікування,	у	моменти	часу	I	та	II,	тобто	під	час	першої	реєстрації	та	
за	рік,	UTI	та	UTII	відповідно),	та	у	здорових	людей	(контроль);	1-3 відповідають	локусам	відведення	Fz,	Cz,	та	Pz.
I II
* *
* *
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a	marginal	 significance.	When	 comparing	 the	 three	
examined	groups,	the	reaction	time	showed	significant	
increases	 in	 the	case	of	 the	RRMS	groups	during	 the	
first	recording	(Fig.	6).
DISCUSSION
Evoked-potential	 techniques	 were	 applied	 in	 MS	
diagnosis	 together	 with	 imagery,	 being	 a	 useful,	
complementary,	 and	 objective	 measure	 oriented	
toward	 the	 state	 of	 the	 function	 and	 the	 loss	 of	 it.	
From	this	aspect,	there	is	a	wide	consensus	[1],	at	least	
regarding	the	VEPs.	Our	findings	enhance	a	series	of	
studies	that	led	to	the	use	of	EPs	for	the	diagnosis	of	
MS.	The	latencies	of	the	most	important	components,	
the	N75,	P100,	and	N135	waves,	 increase	in	 the	case	
of	all	MS	patients,	regardless	of	the	therapeutic	status,	
when	 compared	with	 the	 control	 (in	 accordance	with	
the	literature,	both	at	 the	beginning	and	at	 the	end	of	
the	study).	A	one-year-long	treatment	with	the	disease-
modifying	drug	showed	no	significant	beneficial	effect	
from	 this	 viewpoint,	 and	 there	 were	 no	 noticeable	
symmetry	differences	between	groups.
The	VEP	amplitudes	showed	 increased	variability,	
otherwise	 true	 for	 all	 evoked	 responses,	 being	
proportional	 to	 the	 section	 of	 the	 conductive	 tracts	
and	influenced	by	a	multitude	of	factors,	such	as	bone	
thickness,	 fatty	 tissue	 presence	 [17],	 alpha	 rhythm	
dominance,	oxygenation	response	to	visual	stimuli,	etc.	
[18].	As	a	consequence,	at	least	in	the	past,	amplitudes	
were	neglected	 in	evaluation	of	EPs.	Still,	 for	visual	
responses,	 they	have	 relevance,	at	 least	 in	acute	and	
subacute	 phases	 of	 retrobulbar	 neuropathy,	when	 an	
amplitude	 reduction	 is	 present	 [19].	This	 reduction,	
combined	 with	 the	 usually	 unilateral	 presence	 of	
retrobulbar	 optical	 neuropathy,	 lends	 support	 to	 our	
findings	[2]	(overall,	significant	partial	asymmetry	of	
the	amplitudes	 for	 the	N75	component	 in	 the	RRMS	
groups	vs	control).	As	a	consequence,	we	observe	that	
the	 latency	 asymmetry	 recovers	 more	 rapidly	 than	
the	amplitude	 in	 the	case	of	VEPs	 (remyelination	vs 
axonal	loss,	but	without	a	quantifiable	influence	of	the	
applied	treatment).	
An	 intriguing	 aspect	 is	 the	VEP	morphology.	The	
normal	 aspect,	 one	 marked	 positive	 deflection,	 the	
P100	 wave,	 is	 sometimes	 bifid,	 forming	 either	 a	
doubled	wave	 if	 the	 interpeak	 latency	 difference	 is	
under	10	msec,	or	a	W-shaped	one	(the	same	difference	
being	 between	 10-50	 msec),	 or	 individual	 waves,	
even	 more	 than	 two,	 when	 the	 difference	 is	 longer	
than	 50	msec.	The	W	 shape	 appears	 in	 an	 increased	
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F i g. 5.	P300	amplitudes	in	the	three	examined	groups.	Designations	are	the	same	as	in	Fig.	4.
Р и с. 5.	Значення	амплітуди	потенціалу	P300	у	трьох	обстежених	групах.
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F i g. 6.	Neurofeedback	 parameters	 (hits,	 false	 hits,	 and	 reaction	
time,	1-3,	respectively)	in	the	three	examined	groups.	Designations	
are	the	same	as	in	Fig.	5.	
Р и с. 6.	Параметри	зворотного	зв’язку	(співпадіння,	неспівпа-
діння	та	затримка	реакції,	1–3	відповідно)	у	трьох	обстежених	
групах.
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proportion	 in	MS	 patients	 [20].	 This	 was	 observed	
vs	 control	 in	 our	 study	 too,	 in	 accordance	 with	 the	
literature	 [21].	A	 one-year-long	 treatment	 with	 GA	
seems,	quite	 interestingly,	 to	 increase	 the	occurrence	
of	 the	mentioned	morphology	 when	 compared	 with	
untreated	 MS	 patients.	 We	 are	 lacking	 a	 feasible	
explanation	with	 respect	 to	 this	 point;	 we	 can	 only	
suppose	 that	 GA	 might	 enhance	 the	 occurrence	 of	
oscillatory	responses,	probably	by	inducing	a	function-
compensating	 mechanism.	 These	 changes,	 like	 the	
gamma	oscillatory	response	[22],	can	distort	the	VEP,	
causing	the	abnormal	waveform.	
The	 P300	 component	 of	 the	 auditory	 cognitive	
EP	was	 investigated	 in	order	 to	evaluate	 if	cognitive	
dysfunction	is	detectable	by	the	method.	The	technique	
has	 not	 enjoyed	 a	 wide	 clinical	 use	 but	 was	 used/
implemented	 already	 in	 other	 conditions	 also,	 such	
as	 dementia	 [23],	ADHD,	 and/or	 epilepsy	 [24],	 etc.	
Our	 subjects	were	 at	 the	 initial	 stage	 of	 the	 disease	
(as	 the	EDSS	 score	 showed),	 and	 it	 can	be	 assumed	
that	 cognitive	 changes	 were	 slight,	 if	 existent.	 The	
situation	is	reflected	also	by	the	considerably	reduced	
latency	 values	 when	 compared	 with	 the	 control	 (in	
contradiction,	 at	 least	 for	 now,	 with	 the	 literature	
[10]).	 After	 one	 year	 of	 treatment	 with	 GA,	 an	
increase	 in	 the	 latency	was	noticed	 (with	an	obscure	
significance),	 contrasting	 with	 the	 untreated	 group	
and	 accompanied	 by	 an	 increase	 in	 the	 amplitudes.	
We	can	only	hypothesize	 that	 a	 compensatory	effect	
was	 induced	 during	 the	GA	 treatment,	 either	 by	 the	
drug	or	by	an	 intrinsic	mechanism.	On	 the	one	hand,	
the	 number	 of	 recruited	 pathways	 required	 for	 the	
response	 generation	 increases,	 and,	 due	 to	 this,	 the	
amplitude	 increases.	On	 the	 other	 hand,	 the	 latency	
prolongation	suggests	that	the	treatment	exerts	a	week	
influence	on	 the	process	 of	 remyelination	 (probably	
due	 to	 the	 relatively	 short	 period	 of	 evaluation,	 as	
opposed	to	the	literature	[25]).	 	
Neurofeedback	 set t ings	 are	 represented	 by	
the	 cognitive	 tasks	 and	 the	 resulting	 parameters,	
when	 eliciting	 the	 auditory	 P300	 using	 the	 oddball	
paradigm.	Multiple	 sclerosis	patients	demonstrate	an	
increased	 reaction	 time,	which	 is	 used	 as	 a	measure	
of	 the	 information	processing	 rate	 [26].	Under	 these	
circumstances,	our	data	suggest	some	beneficial	effect	
of	GA	treatment	in	clinical	terms;	the	reaction	time	is	
somewhat	 reduced,	compared	with	 the	 initial	values,	
and	 the	 number	 of	 hits	 increased	 (despite	 only	with	
marginal	significance),	which	might	 increase	with	an	
increased	number	of	cases.	
The	 limits	 of	 our	 study	 are	 the	 following.	 The	
performed	 neurophysiological	 tests	 delivered	 an	
impressive	 amount	 of	 data,	 which,	 combined	 with	
the	doubled	statistical	analysis,	hopefully	neutralized	
one	of	 the	 limits	of	our	 study,	namely	participation-
induced	 variability	 and	 the	 relatively	 small	 group	
sizes.	Another	 concern	 is	 the	 duration	 of	 treatment.	
In	order	 to	establish	whether	a	one-year-long	follow-
up	permits	or	not	a	proper	validation	of	all	potential	
effects	of	GA	in	MS,	further	investigations	are	needed.
Thus,	 the	VEP	 latencies	 in	both	RRMS	groups	are	
longer	when	compared	with	healthy	 individuals,	 and	
GA	shows	no	 impact	 from	 this	aspect	after	one	year	
of	continuous	 treatment.	Partial	amplitude	variability	
(N75	 reduction)	 is	 noticeable	 in	 RRMS	 groups,	
compared	with	the	control,	and	W-like	morphology	of	
VEPs	is	increased	after	GA	treatment.
For	 the	P300	wave,	both	 latencies	and	amplitudes	
(Cz	and	Pz	recordings)	 increased	after	GA	treatment.	
Untreated	RRMS	patients	 showed	also	 an	amplitude	
increase.	A	trend	toward	induction	of	the	reaction	time	
is	noticeable	after	one-year-long	GA	treatment.
Further	research	is	needed	to	evaluate	if	this	relative	
lack	of	electrophysiological	improvement	is	persistent	
even	 in	 the	 case	 where	 the	 investigation	 period	 is	
prolonged.
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Р	е	з	ю	м	е
Розсіяний	склероз	–	запальне	неврологічне	захворювання,	
від	якого	страждають	молоді	люди,	яке	спричиняє	численні	
терапевтичні	проблеми	і	призводить	до	тяжкої	інвалідизації.	
Глатирамер	ацетат	(ГА)	є	одним	із	препаратів,	що	модифіку-
ють	захворювання,	і	використовується	часто	для	впливають	
на	захворювання;	він	часто	використовується	для	лікуван-
ня	пацієнтів	 із	такою	патологією.	Ми	досліджували	вплив	
лікування	 із	 застосуванням	ГА	на	параметри	 зорових	ВП,	
які	виникали	після	пред’явлення	реверсивного	патерну,	та	
пов’язаного	з	подією	потенціалу	P300	 (що	відбивають	го-
строту	зору	та	когнітивну	дисфункцію	відповідно).	Пацієн-
ти,	які	страждали	від	розсіяного	склерозу	(ті,	що	пройшли	
однорічний	безперервний	лікувальний	курс	 із	 застосуван-
ням	ГА,	та	ті,	що	не	піддавалися	такій	терапії,	модифіку-
ючій	 захворювання),	 і	 здорові	 суб’єкти	 (контроль)	 брали	
участь	у	дослідженні.	Згадані	параметри	аналізували	у	двох	
моментах	часу	–	при	першій	реєстрації	та	через	рік.	Вияв-
лено,	що	ГА	не	демонстрував	 істотних	ефектів	щодо	пара-
метрів,	що	вивчалися,	в	усякому	разі	в	межах	одного	року.	
Цей	факт	суперечить	багатьом	описаним	клінічним	спосте-
реженням.	
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